Literature DB >> 22129678

Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity.

Patricia Giblin1, Rainer Boxhammer, Sudha Desai, Rachel Kroe-Barrett, Gale Hansen, John Ksiazek, Maret Panzenbeck, Kerry Ralph, Racheline Schwartz, Clare Zimmitti, Catrin Pracht, Sandra Miller, Jeanne Magram, Tobias Litzenburger.   

Abstract

PAR-2 belongs to a family of G-protein coupled Protease-Activated Receptors (PAR) which are activated by specific proteolytic cleavage in the extracellular N-terminal region. PAR-2 is activated by proteases such as trypsin, tryptase, proteinase 3, factor VIIa, factor Xa and is thought to be a mediator of inflammation and tissue injury, where elevated levels of proteases are found. Utilizing the HuCAL GOLD® phage display library we generated fully human antibodies specifically blocking the protease cleavage site in the N-terminal domain. In vitro affinity optimization resulted in antibodies with up to 1000-fold improved affinities relative to the original parental antibodies with dissociation constants as low as 100 pM. Corresponding increases in potency were observed in a mechanistic protease cleavage assay. The antibodies effectively inhibited PAR-2 mediated intracellular calcium release and cytokine secretion in various cell types stimulated with trypsin. In addition, the antibodies demonstrated potent inhibition of trypsin induced relaxation of isolated rat aortic rings ex vivo. In a short term mouse model of inflammation, the trans vivo DTH model, anti-PAR-2 antibodies showed inhibition of the inflammatory swelling response. In summary, potent inhibitors of PAR-2 were generated which allow further assessment of the role of this receptor in inflammation and evaluation of their potential as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129678     DOI: 10.3233/HAB-2011-0243

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN: 1093-2607


  3 in total

Review 1.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

2.  Structural insight into allosteric modulation of protease-activated receptor 2.

Authors:  Robert K Y Cheng; Cédric Fiez-Vandal; Oliver Schlenker; Karl Edman; Birte Aggeler; Dean G Brown; Giles A Brown; Robert M Cooke; Christoph E Dumelin; Andrew S Doré; Stefan Geschwindner; Christoph Grebner; Nils-Olov Hermansson; Ali Jazayeri; Patrik Johansson; Louis Leong; Rudi Prihandoko; Mathieu Rappas; Holly Soutter; Arjan Snijder; Linda Sundström; Benjamin Tehan; Peter Thornton; Dawn Troast; Giselle Wiggin; Andrei Zhukov; Fiona H Marshall; Niek Dekker
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

Review 3.  Protease-activated receptor-2: Role in asthma pathogenesis and utility as a biomarker of disease severity.

Authors:  Vivek Dipak Gandhi; Nami Shrestha Palikhe; Harissios Vliagoftis
Journal:  Front Med (Lausanne)       Date:  2022-07-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.